Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01822691 · ClinicalTrials.gov registry record · Phase 2
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01822691 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 15 participants.
The verdict
NCT01822691, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary purpose of this research study is to assess whether the participant's disease, Myelodysplastic Syndromes (MDS), responds favorably to INCB024360. The study will also evaluate the long-term outcomes of the participant's disease after they have finished taking INCB024360.
Interventions
- DRUG INCB024360
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01822691
The ClinicalTrials.gov registry entry for NCT01822691 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB024360 is the first listed.
NCT01822691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01822691 about?
NCT01822691 is a clinical study titled "Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)". The primary purpose of this research study is to assess whether the participant's disease, Myelodysplastic Syndromes (MDS), responds favorably to INCB024360. The study will also evaluate the long-term outcomes of the participant's disease after they have finished taking INCB024360.
What is the current status of trial NCT01822691?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2013-07. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01822691?
The interventions under investigation include: INCB024360 (DRUG).
Who is sponsoring clinical trial NCT01822691?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.